This result was consistent with the findings of the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy Study) trial, in which an independent relationship was identified between IL-6 and a higher risk of stroke and major bleeding independent of clinical risk factors, even after adjusting for cardiovascular biomarkers to attenuate the prognostic value (29). This evidence concerns the gene IL6 and Stroke.